Business · 28/10/20261 min read
Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure (MCM) Priority Review Voucher; Bixlenvo (Bictegravir and Lenacapavir)
Summary
The Food and Drug Administration (FDA) is announcing the approval of a product redeeming a material threat MCM priority review voucher.
Original source language: Federal Register — Health and Human ServicesOpen original release →